RxSight (RXST) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
STAAR Surgical (STAA) has outperformed RxSight (RXST) over the past year, losing 16.3% versus a loss of 42.0%. Over five years, RXST leads with a -64.6% price change compared with -80.5% for STAA. STAAR Surgical is the larger company by market cap ($1.12 billion vs $199.6 million), about 5.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXST | STAA |
|---|---|---|
| Share price | $4.80 | $22.36 |
| Market cap | $199.65M | $1.12B |
| 1-day change | +3.23% | +0.95% |
| YTD return | -53.93% | -3.16% |
| 1-year return | -42.03% | -16.32% |
| 5-year return | -64.60% | -80.54% |
| P/E ratio (TTM) | — | 279.50 |
| Forward P/E | — | 20.12 |
| EPS (TTM) | $-1.17 | $0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.22 | $35.87 |
| 52-week low | $4.48 | $15.59 |
| Distance from 52-week high | -63.69% | -37.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +57.71% | +25.22% |
| Average volume | 861.88K | 1.00M |
| Shares outstanding | 41.59M | 50.14M |
| Employees | 461 | 921 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STAAR Surgical is about 5.6 times larger than RxSight by market value ($1.12B vs $199.65M).
- STAA has outperformed RXST by 25.7 percentage points over the past year.
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Health Care · Ophthalmic Goods · 461 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
RXST vs STAA FAQ
Which is bigger, RxSight or STAAR Surgical?
STAAR Surgical (STAA) is larger, with a market capitalization of $1.12B compared with $199.65M for RxSight (RXST).
Which stock has performed better over the past year, RXST or STAA?
STAA returned -16.32% over the past 12 months, compared with -42.03% for RXST (price return, excluding dividends). Past performance does not predict future results.
Are RxSight and STAAR Surgical in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.